drugset / Trial / NCT03787368
End-stage Renal Disease (ESRD) Pilot Study
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the safety of two different doses of a drug called BAY1213790 and how well it is tolerated in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). Approximately 40, with up to 60 study patients will take part in the study.
Timeline
- Start
- 2019-01-31
- Primary completion
- 2021-09-15
- Completion
- 2021-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osocimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.